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Abstract
P-glycoprotein, encoded by the ABCB1 gene, may modulate the brain concentration of several
antidepressants. Functional genetic variation is thought to exist in this gene, and here we review
several studies that have attempted to associate this variation with clinical response to antidepressant
treatment.
Introduction and context
Major depression is one of the most common and
debilitating psychiatric disorders [1]. The most common
first line pharmacotherapy for depression is selective
serotonin uptake inhibitors (SSRIs). Unfortunately, only
approximately one-third of patients achieve remission
(absence of depressive symptoms) after an adequate trial
of a single SSRI [2]. Among other possible causes, genetic
variation in relevant pharmacokinetic genes may be one
factor that leads to variable patient response to SSRIs.
P-glycoprotein, which is encoded by the ABCB1 gene
(also known as MDR1), is an ABC-transporter that is
expressed in many tissues, including the liver, intestines
and endothelial cells of the blood-brain barrier [3]. The
function of P-glycoprotein is to facilitate the transport of
a broad range of endogenous and xenobiotic molecules
across cellular membranes. Of particular relevance is the
protein's role in the blood-brain barrier, where in vivo
studies of mice deficient for the ABCB1 gene have shown
that P-glycoprotein may play a part in modulating the
concentration of certain antidepressants in the brain.
Studies using ABCB1 knockout mice by Uhr and
colleagues [4–7] have shown that amitriptyline, trimi-
pramine, venlafaxine, doxepin and the SSRIs, citalopram
and paroxetine, appear to be substrates of P-glycopro-
tein, while melperone, mirtazapine, and the SSRI
fluoxetine do not. However, contradictory evidence
suggesting that citalopram is not a substrate for
P-glycoprotein was observed by other groups utilizing
different in vitro model systems. Using monolayers of
bovine brain microvessel endothelial cells, Rochat et al.
[8] showed no change in citalopram efflux with the
potent P-glycoprotein inhibitor, cyclosporin A, indicat-
ing that citalopram is not actively transported by
P-glycoprotein. In a large-scale study investigating the
active transport of many drugs, Mahar Doan and
colleagues [9] found citalopram was not strongly
transported across monolayers of a Madin-Darby canine
kidney (MDCK type II) cell line stably transfected with
ABCB1. In addition, utilizing both a porcine kidney
epithelial cell line (LLC-PK1) stably transfected with
ABCB1 and primary porcine brain capillary endothelial
cells as model systems, Weiss et al. [10] showed that
citalopram and venlafaxine were not strong inhibitors of
P-glycoprotein.
Naturally occurring DNA variation in the human ABCB1
gene has been shown to affect the function of
P-glycoprotein [11]. Thus, it is reasonable to hypothesize
that a portion of the variation in response to antide-
pressants may be due to inter-patient variability in
P-glycoprotein function. Three common variants in
linkage disequilibrium in the ABCB1 gene have been
repeatedly investigated in association studies; the synon-
ymous C1236T single nucleotide polymorphism (SNP;
rs1128502) in exon 12, the non-synonymous SNP
G2677T/A (rs2032582) in exon 2, and the synonymous
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Hoffmeyer et al. [11] showed that the C3435T SNP
leads to variable expression of P-glycoprotein in the
intestines, although this effect has not been observed in
all studies [12].
One of the earliest association studies of ABCB1 genetic
variants and response to antidepressants involved 55
subjects with bipolar disorder treated with a variety of
antidepressants [13]. The C3435T SNP genotype status of
26 subjects with a history of antidepressant-induced
mania were compared to 29 age, ethnicity and gender
matched subjects without a history of antidepressant-
induced mania. This study observed no association
between antidepressant-induced mania and the
C3435T SNP in the ABCB1 gene in this clinical
population.
Major recent advances
A study by Laika and colleagues [14] investigated the
association between the G2677T/A SNP and response to
treatment with amitriptyline, a tricyclic antidepressant.
This study involved 50 Caucasian inpatients with major
depressive disorder that received a fixed dose of 75 mg
amitriptyline for 3 weeks. The authors utilized the
Hamilton Depression Rating Scale (HAM-D) and Clin-
ical Global Impression Scale to gauge therapeutic
response and the Dosage Record and Treatment Emer-
gent Symptoms Scale (DOTES) to gauge subjects' side-
effect profiles. No association between the G2677T/A
SNP and therapeutic response, side-effects or mean
serum concentration of amitriptyline after 3 weeks of
treatment was observed. Interestingly, the authors pre-
viously reported an association between functional
polymorphisms in CYP2C19 and CYP2D6 and response
to amitriptyline in the same clinical population [15].
In a recent study by Fukui et al.[16], the C3435T SNP was
investigated and shown to affect mean fluvoxamine
plasma concentration. This study involved 62 Japanese
outpatients, of which 55 were diagnosed with major
depressive disorder. Subjects were given fluvoxamine in
50 mg/day increments up to a 200 mg/day dosage.
Serum levels were obtained after 2 weeks on the same
dosage in order to obtain steady state levels. Association
between plasma concentration and C3435T genotype
was observed at the 200 mg/day dosage, but not at the
150 mg/day, 100 mg/day, or 50 mg/day dosages.
In a larger study by Uhr and colleagues [7], the authors
investigated the association of ABCB1 variants with
antidepressant remission. The study included 443 inpa-
tients with major depression that were treated with a
variety of antidepressants and evaluated with the HAM-D
rating scale. The authors genotyped these subjects for
G2677T/A and C3435T SNPs, as well as 93 other variants
in the ABCB1 gene and tested them for association with
remission (HAM-D < 10) at treatment weeks 4, 5, and 6.
The G2677T/A and C3435T SNPs were not associated
with remission; however, two haplotype blocks were
associated with remission at week 4 (P = 0.0003), week 5
(P = 0.008) and week 6 (P = 0.007) in subjects taking
putative P-glycoprotein substrates (amitriptyline, citalo-
pram, paroxetine, or venlafaxine). Interestingly, the
association was not observed in subjects taking the
putative non-P-glycoprotein substrate mirtazapine.
The associated SNPs were contained in intronic regions
of the gene and were captured by two haplotype blocks,
one containing SNPs rs2235067, rs4148740, rs2032583,
rs4148739, rs11983225, rs2235040, and rs12720067,
and the other containing SNPs rs7787082 and
rs10248420. Within each block, the reported SNPs
were highly correlated with one another. The authors
note that the associated variants exhibit strong ethnic
differences in allele frequencies and speculate that these
variants could contribute to the ethnic differences seen in
clinical response to antidepressants.
In a study utilizing the much larger Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) clinical
trial population, Peters and colleagues [17] investigated
the association of ABCB1 variants and response to the
SSRI citalopram. In an effort to limit type I error, the
authors utilized a two-stage approach for analysis.
Within each ethnic group, clinical response and gender,
the subjects were randomly split into a discovery (n =
831) and validation sample (n = 1,046) set. Variants that
were associated at P < 0.05 in the discovery set were
investigated in the validation set. Clinical response was
assessed using the Quick Inventory of Depressive
Symptomatology (QIDS) scale. The authors observed
no association between the ABCB1 variants investigated
(C1236T, G2677T/A, and C3435T) and citalopram
response, response specificity, remission, or intolerance
after at least 6 weeks of treatment. While not the original
focus of their study, the authors also report data
regarding the ABCB1 SNPs associated with remission
from Uhr et al. [7]. As part of a genome-wide association
study, two of the variants in the first haplotype block
reported by Uhr et al. were genotyped in the discovery
sample set and were not associated with citalopram
remission in the STAR*D population. Unfortunately, the
authors did not have genotype data on the second
haplotypeblock reported by Uhr et al.[7], and thus could
not test whether this region was associated with
antidepressant response.
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Kato et al. [18] investigated the association between the
C1236T, G2677T/A, and C3435T SNPs and response to
the SSRI paroxetine. Subjects were scored for depression
severity using the HAM-D rating scale, and the authors
used linear regression to test for association between the
variants and percent decrease of HAM-D score from
baseline. A significant association was observed between
the G2677T/A SNP and paroxetine response at week 6
(P = 0.01), though no associations were observed with
the other two SNPs. Interestingly, the authors noted that
the variants were not in linkage disequilibrium as strong
as previously reported, which they attributed to the small
sample size used in this study.
Future directions
Some studies have suggested that P-glycoprotein may
modulate brain concentrations of certain antidepressant
drugs [4–7], while other studies indicate weak or no
interaction between antidepressants and P-glycoprotein
[8–10]. Despite this conflicting evidence, several studies
to date have further investigated the effect of ABCB1
variation and clinical response to antidepressants.
Results have been equivocal, with many studies failing
to report a strong association. There are several possible
reasons for these conflicting results, including limited
sample sizes, differing statistical methods, phenotypic
heterogeneity, or population stratification. These factors
are also thought to confound genetic association studies
with other complex phenotypes [19]. A careful meta-
analysis of the data may give insight into any true genetic
effects. Furthermore, standardization of clinical response
phenotype definitions would help mitigate risks of
missing true effects. Given that the functional effects of
the three most commonly studied ABCB1 variants are
not completely understood and may in fact be in linkage
disequilibrium with the true causative variants, more
work is needed to understand the genetic architecture of
this gene and the functional and clinical impact of both
common and rare variants. The study by Uhr et al. shows
that comprehensive genotyping of the entire ABCB1
locus may be preferable to simple assessment of a small
set of putatively functional variants. Finally, in order to
fully dissect the role of ABCB1 variants in response to
antidepressants, well-powered, prospective clinical trials
need to be initiated.
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